MedTrace Logo

Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months

NCT04108845 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-09-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged above 3 Months.

Conditions

  • Pneumonia, Pneumococcal

Interventions

BIOLOGICAL

15-Valent Pneumococcal Conjugate Vaccine

3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.

Sponsors & Collaborators

  • Hebei Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Laishui Center for Disease Control and Prevention

    collaborator UNKNOWN

  • National Institutes for Food and Drug Control, China

    collaborator OTHER

  • Simoon Record Pharma Information Consulting Co., Ltd.

    collaborator INDUSTRY

  • Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Du Lin, Master · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-05
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04108845 on ClinicalTrials.gov